Time to treatment: A crucial factor in thrombolysis and primary angioplasty

Journal of Thrombosis and Thrombolysis

Volumn 3, Issue 3, 1996, Pages 249-255

  Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute myocardial infarction; Primary angioplasty; Thrombolysis; Time to treatment

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ANGIOPLASTY; BLOOD CLOT LYSIS; CLINICAL PROTOCOL; CLINICAL TRIAL; HEART MUSCLE REPERFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0029737297     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00181669     Document Type: Review

References (43)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360.
3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
4. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded? Circulation 1989;79:441-444.
5. Braunwald E. The open-artery theory is alive and well - again. N Engl J Med 1993;329:1650-1652.
6. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. Drugs 1992;44:293-325.
7. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
8. The GUSTO Angiographic Investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
9. Cannon CP, McCabe CH, Diver DJ, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994;24:1602-1610.
10. Stadius ML, Davis K, Maynard C, Ritchie JL, Kennedy JW. Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction. Circulation 1986;74:701-711.
11. Dalen JE, Gore JM, Braunwald E, et al. Six- and twelve-month follow-up of the Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. Am J Cardiol 1988;62:179-185.
12. Belenkie I, Thompson CR, Manyari DE, et al. Importance of effective, early and sustained reperfusion during acute myocardial infarction. Am J Cardiol 1989;63:912-916.
13. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial; Phase I findings. N Engl J Med 1985; 312:932-936.
14. Flygenring BP, Sheehan FH, Kennedy JW, Dodge HT, Braunwald E, for the TIMI Investigators. Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival? (abstr). J Am Coll Cardiol 1991;17(Suppl A):275A.
15. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.
16. Lincoff AM, Topol EJ, Califf RM, et al. Significance of a coronary artery with Thrombolysis in Myocardial Infarction grade 2 flow "patency" (outcome in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trials). Am J Cardiol 1995;75:871-876.
17. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel K-F, Neuhaus K-L. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993;21:1391-1395.
18. Cannon CP, Braunwald E. GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol 1994;49:1-8.
19. Simes RJ, Topol EJ, Holmes DR, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923-1928.
20. Timm TC, Ross R, McKendall GR, Braunwald E, Williams DO, and the TIMI Investigators. Left ventricular function and early cardiac events as a function of time to treatment with t-PA: A report from TIMI II (abstr). Circulation 1991; 84:II230.
21. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. Circulation 1995;91:1659-1668.
22. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103-2114.
23. O'Keefe JH, Rutherford BD, McConahay DR, et al. Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1989;64:1221-1230.
24. Braunwald E. Optimizing thrombolytic therapy of acute myocardial infarction. Circulation 1990;82:1510-1513.
25. National Heart Attack Alert Program Coordinating Committee - 60 Minutes to Treatment Working Group. Emergency department: Rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994;23:311-329.
26. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm - paradoxic or predictable? Circulation 1993;88:296-306.
27. Lambrew CT. The National Heart Attack Alert Program: A review. J Thromb Thrombolysis 1994;1:153-156.
28. Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis 1994;1:27-34.
29. Lambrew CT. Emergency department triage of patients with nontraumatic chest pain. ACC Curr J Rev 1995;4: 61-62.
30. Krall SP, Reese CL, Donahue L. Effect of continuous quality improvement methods on reducing triage time to thrombolytic interval for acute myocardial infarction. Acad Emerg Med 1995;2:603-609.
31. Kopecky SL, Siska MJ, Jurek JA, et al. Method of reducing emergency room time to treatment of acute myocardial infarction (abstr). J Am Coll Cardiol 1995;(Special Issue): 206.
32. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase 1: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:142-154.
33. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico: GISSI-2. A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
34. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
35. Cannon CP, Love TW, McCabe CH, et al. TNK-tissue plasminogen activator in myocardial infarction (TIMI) 10: Results of the initial patients in the TIM 10 Pilot-a Phase 1, pharmacokinetics trial (abstr). Circulation 1995;92(Suppl I):I-415.
36. Weaver WD, Bode C, Burnett C, et al. Reteplase vs. Alteplase Patency Investigation During myocardial infarction trial (RAPID 2) (abstr). J Am Coll Cardiol 1995;Special Issue:87A.
37. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
38. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.
39. Cannon CP, Henry TD, Schweiger MJ, et al. Current management of ST elevation myocardial infarction and outcome of thrombolytic ineligible patients: Results of the multicenter TIMI 9 Registry (abstr). J Am Coll Cardiol 1995;Special Issue:231A-232A.
40. Tiefenbrunn AJ, Chandra NC, French WJ, Rogers WJ. Experience with primary PTCA compared to alteplase in patients with acute myocardial infarction (abstr). Circulation 1995;92(Suppl I):I-138.
41. Rogers WJ, Dean LS, Moore PB, et al. Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1994;74:111-118.
42. Pell ACH, Miller HC, Robertson CE, Fox KAA. Effect of "fast track" admission for acute myocardial infarction on delay to thrombolysis. Br Med J 1992;304:83-87.
43. Topol EJ, Califf RM, Lee KL, on behalf of the GUSTO Investigators. More on the GUSTO trial (letter). N Engl J Med 1994;331:277-278. Published errata appear in N Engl J Med 1994;331:687, and 1994;331:1323.